Haystack Oncology, Inc.
Haystack Oncology, Inc., a pioneering force in the biotechnology sector, is headquartered in the United States. Founded in 2018, the company has rapidly established itself as a leader in the development of innovative cancer diagnostics and therapeutics. Haystack Oncology focuses on utilising advanced genomic technologies to enhance precision medicine, particularly in the realm of oncology. The company’s flagship products include cutting-edge liquid biopsy tests that enable early cancer detection and monitoring, setting them apart in a competitive market. With a commitment to improving patient outcomes, Haystack Oncology has achieved significant milestones, including collaborations with leading research institutions. Their unique approach to cancer care positions them as a notable player in the industry, dedicated to transforming the landscape of cancer treatment through science and innovation.
DitchCarbon Score
How does Haystack Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Haystack Oncology, Inc.'s score of 31 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Haystack Oncology, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Quest Diagnostics Incorporated, which provides emissions data that may be relevant to Haystack's climate commitments. As of now, there are no documented reduction targets or climate pledges specific to Haystack Oncology. The absence of direct emissions data suggests that the company may rely on the sustainability initiatives and performance metrics of its parent organisation, Quest Diagnostics. This relationship indicates that any climate commitments or emissions reductions may be influenced by the broader corporate strategies of Quest Diagnostics. In the context of the industry, it is essential for companies like Haystack Oncology to align with established climate frameworks and targets, such as those set by the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific initiatives or targets have not been disclosed for Haystack Oncology at this time. Overall, while direct emissions data and reduction commitments are not available, the company's affiliation with Quest Diagnostics may provide a pathway for future climate action and sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 83,929,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 145,724,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 41,299,000 | 00,000,000 | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Haystack Oncology, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
